TY - JOUR
T1 - The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy
T2 - An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
AU - Sia, Tiffany Y.
AU - Tew, William P.
AU - Purdy, Christopher
AU - Chi, Dennis S.
AU - Menzin, Andrew W.
AU - Lovecchio, John L.
AU - Bookman, Michael A.
AU - Cohn, David E.
AU - Teoh, Deanna G.
AU - Friedlander, Michael
AU - Bender, David
AU - Mutch, David G.
AU - Gershenson, David M.
AU - Tewari, Krishnansu S.
AU - Wenham, Robert M.
AU - Wahner Hendrickson, Andrea E.
AU - Lee, Roger B.
AU - Gray, Heidi J.
AU - Secord, Angeles Alvarez
AU - Van Le, Linda
AU - Lichtman, Stuart M.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/6
Y1 - 2023/6
N2 - Objective: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. Methods: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared. Results: We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09–1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04–1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00–3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00–1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. Conclusions: In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov:
AB - Objective: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. Methods: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared. Results: We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09–1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04–1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00–3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00–1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. Conclusions: In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov:
UR - http://www.scopus.com/inward/record.url?scp=85154586593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85154586593&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2023.03.018
DO - 10.1016/j.ygyno.2023.03.018
M3 - Article
C2 - 37148580
AN - SCOPUS:85154586593
SN - 0090-8258
VL - 173
SP - 130
EP - 137
JO - Gynecologic oncology
JF - Gynecologic oncology
ER -